Zorevunersen sodium is under clinical development by Stoke Therapeutics and currently in Phase II for Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy). According to GlobalData, Phase II drugs for Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) have an 88% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Zorevunersen sodium’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Zorevunersen sodium overview
Zorevunersen sodium (STK-001) is under development for the treatment of Dravet syndrome. It is administered via intrathecal route. It is developed based on targeted augmentation of nuclear gene output (TANGO) technology, RNA splicing. The therapeutic candidate increases productive SCN1 mRNA and consequently restore levels of Nav1.1 protein.
See Also:
Stoke Therapeutics overview
Stoke Therapeutics is a biotechnology company. It develops antisense oligonucleotide which targets RNA splicing to enhance gene expression for the treatment of genetic diseases. The company is developing programs that are in preclinical development for eye and dravet syndrome and central nervous system conditions. Stoke Therapeutics harnesses targeted augmentation of nuclear gene output (TANGO) technology to develop its product portfolio. The company’s pipeline products address the diseases of dravet syndrome and autosomal dominant optic atrophy. Stoke Therapeutics is headquartered in Bedford, Massachusetts, the US.
For a complete picture of Zorevunersen sodium’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
